Immunovant Stock (NASDAQ:IMVT)
Previous Close
$25.22
52W Range
$24.67 - $45.58
50D Avg
$29.33
200D Avg
$30.09
Market Cap
$3.76B
Avg Vol (3M)
$879.71K
Beta
0.71
Div Yield
-
IMVT Company Profile
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
IMVT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AMLX | Amylyx Pharmaceuticals, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| ETNB | 89bio, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| ABUS | Arbutus Biopharma Corporation |
| BPMC | Blueprint Medicines Corporation |
| APLS | Apellis Pharmaceuticals, Inc. |
| AKRO | Akero Therapeutics, Inc. |
| KRTX | Karuna Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ARQT | Arcutis Biotherapeutics, Inc. |
| PLRX | Pliant Therapeutics, Inc. |
| LEGN | Legend Biotech Corporation |